Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$0.50
$0.48
$0.36
$7.31
$7.46M1.9876,300 shsN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.20
-1.6%
$1.18
$0.72
$6.45
$11.81M0.22399,218 shs250,218 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
$0.00
$6K1.6183,499 shsN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
$14.75
$110K1.37120,908 shs23,886 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-1.61%+7.02%-2.40%+60.02%-76.83%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%+150.00%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%-95.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
2.1615 of 5 stars
0.04.00.04.72.40.80.6
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
$3.51M2.13N/AN/A$2.45 per share0.21
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/A-237.65%57.29%N/A

Latest TCON, GNCA, AYLA, and BCLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
N/A
2.28
2.28
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
AYLA
Ayala Pharmaceuticals
3514.82 million14.29 millionNot Optionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
409.84 million8.74 millionOptionable
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data

Recent News About These Companies

Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
Tracon: Q1 Earnings Snapshot
TRACON Pharmaceuticals Inc
TRACON announces 1-for-20 reverse stock split
TRACON Pharmaceuticals Announces Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:AYLA

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.20 -0.02 (-1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.21 +0.01 (+1.17%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.